BREAKING
Eli Lilly and Company (LLY) to acquire Orna Therapeutics 2 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 2 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 3 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 4 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 6 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 6 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 7 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 7 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 7 hours ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 3 days ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 2 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 2 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 3 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 4 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 6 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 6 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 7 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 7 hours ago Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap 7 hours ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 3 days ago
ADVERTISEMENT
AlphaGraphs

Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025

Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today. Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was 7.1%. GAAP net earnings increased 49% to $5.1 billion, or $2.10 per share, compared to last year. Adjusted EPS grew 20.6% to $2.46. For the full year of 2026, JNJ […]

$JNJ January 21, 2026 1 min read

Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2025 earnings results today.

Reported sales increased 9.1% year-over-year to $24.56 billion. Operational sales growth was 7.1%.

GAAP net earnings increased 49% to $5.1 billion, or $2.10 per share, compared to last year. Adjusted EPS grew 20.6% to $2.46.

For the full year of 2026, JNJ expects reported sales of $100-101 billion and adjusted EPS of $11.43-11.63.

Prior performance

ADVERTISEMENT
ADVERTISEMENT